Page 21 - Functional impairment and cues for rehabilitation of head and neck cancer patients -
P. 21
55. Langmore S, Krisciunas GP, Miloro KV, Evans SR, Cheng DM. Does PEG use cause dysphagia in head and neck cancer patients? Dysphagia. 2012;27(2):251-9.
56. Zhang Z, Zhu Y, Ling Y, Zhang L, Wan H. Comparative effects of different enteral feeding methods in head and neck cancer patients receiving radiotherapy or chemoradiotherapy: a network meta-analysis. Onco Targets Ther. 2016;9:2897-909.
57. Silander E, Nyman J, Bove M, et al. Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study. Head & neck. 2012;34(1):1-9.
58. Lewis SL, Brody R, Touger-Decker R, Parrott JS, Epstein J. Feeding tube use in patients with head and neck cancer. Head & neck. 2014;36(12):1789- 95.
59. Wopken K, Bijl HP, Langendijk JA. Prognostic factors for tube feeding dependence after curative (chemo-) radiation in head and neck cancer: A systematic review of literature. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2018;126(1):56-67.
60. Redekop WK, Mladsi D. The faces of personalized medicine: a framework for understanding its meaning and scope. Value Health. 2013;16(6 Suppl):S4-9.
61. Bhayani MK, Hutcheson KA, Barringer DA, et al. Gastrostomy tube placement in patients with oropharyngeal carcinoma treated with radiotherapy or chemoradiotherapy: factors affecting placement and dependence. Head Neck. 2013;35(11):1634-40.
62. Brown TE, Spurgin AL, Ross L, et al. Validated swallowing and nutrition guidelines for patients with head and neck cancer: identification of high- risk patients for proactive gastrostomy. Head & neck. 2013;35(10):1385-91.
63. StromT,Trotti AM, Kish J, et al. Risk factors for percutaneous endoscopic gastrostomy tube placement during chemoradiotherapy for oropharyngeal cancer. JAMA otolaryngology-- head & neck surgery. 2013;139(11):1242-6.
64. Wopken K, Bijl HP, van der Schaaf A, et al. Development and validation of a prediction model for tube feeding dependence after curative (chemo-) radiation in head and neck cancer. PLoS One. 2014;9(4):e94879.
65. Setton J, Lee NY, Riaz N, et al. A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy. Cancer. 2015;121(2):294-301.
66. Bozec A, Benezery K, Chamorey E, et al. Nutritional status and feeding-tube placement in patients with locally advanced hypopharyngeal cancer included in an induction chemotherapy-based larynx preservation program. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2016;273(9):2681-7.
67. Lango MN, Galloway TJ, Mehra R, et al. Impact of baseline patient-reported dysphagia on acute gastrostomy placement in patients with head and neck squamous cell carcinoma undergoing definitive radiation. Head & neck. 2016;38 Suppl 1:E1318-24.
68. Yang W, McNutt TR, Dudley SA, et al. Predictive Factors for Prophylactic Percutaneous Endoscopic Gastrostomy (PEG) Tube Placement and Use in Head and Neck Patients Following Intensity-Modulated Radiation Therapy (IMRT) Treatment: Concordance, Discrepancies, and the Role of Gabapentin. Dysphagia. 2016;31(2):206-13.
69. van der Linden NC, Kok A, Leermakers-Vermeer MJ, et al. Indicators for Enteral Nutrition Use and Prophylactic Percutaneous Endoscopic Gastrostomy Placement in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition. 2017;32(2):225-32.
70. Anderson NJ, Jackson JE, Smith JG, et al. Pretreatment risk stratification of feeding tube use in patients treated with intensity-modulated radiotherapy for head and neck cancer. Head & neck. 2018.
71. Grossberg AJ, Chamchod S, Fuller CD, et al. Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2016;2(6):782-9.
72. Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral oncology. 2017;71:26-33.
73. Kabarriti R, Bontempo A, Romano M, et al. The impact of dietary regimen compliance on outcomes for HNSCC patients treated with radiation therapy. Support Care Cancer. 2018;26(9):3307-13.
74. Nishikawa D, Hanai N, Suzuki H, et al.The Impact of Skeletal Muscle Depletion on Head and Neck Squamous Cell Carcinoma. ORL J Otorhinolaryngol Relat Spec. 2018;80(1):1-9.
75. Sato S, Kunisaki C, Suematsu H, et al. Impact of Sarcopenia in Patients with Unresectable Locally Advanced Esophageal Cancer Receiving Chemoradiotherapy. In Vivo. 2018;32(3):603-10.
76. Tamaki A, Manzoor NF, Babajanian E, et al. Clinical Significance of Sarcopenia among Patients with Advanced Oropharyngeal Cancer. Otolaryngol Head Neck Surg. 2018:194599818793857.
77. Bril SI, Pezier TF, Tijink BM, et al. Preoperative low skeletal muscle mass as a risk factor for pharyngocutaneous fistula and decreased overall survival in patients undergoing total laryngectomy. Head Neck. 2019.
78. Wakabayashi H, Matsushima M, Uwano R, et al. Skeletal muscle mass is associated with severe dysphagia in cancer patients. J Cachexia Sarcopenia Muscle. 2015;6(4):351-7.
79. Wakabayashi H, Takahashi R, Murakami T. The Prevalence and Prognosis of Sarcopenic Dysphagia in Patients Who Require Dysphagia Rehabilitation. J Nutr Health Aging. 2019;23(1):84-8.
1
Introduction
19
